Rituxan succeeds in second Phase III trial in leukaemia
This article was originally published in Scrip
Executive Summary
Genentech/Roche/Biogen Idec's Rituxan/MabThera (rituximab) has succeeded in achieving its primary endpoint in a second Phase III trial, REACH, in chronic lymphocytic leukaemia (CLL), this time in the relapsed setting.